Department of Medical Biosciences, Umeå University, Umeå, Sweden.
Department of Radiation Sciences, Umeå University, Umeå, Sweden.
Cancer Med. 2019 Jan;8(1):311-324. doi: 10.1002/cam4.1917. Epub 2018 Dec 21.
Classification of pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients into CIMP (CpG Island Methylator Phenotype) subgroups has the potential to improve current risk stratification. To investigate the biology behind these CIMP subgroups, diagnostic samples from Nordic pediatric T-ALL patients were characterized by genome-wide methylation arrays, followed by targeted exome sequencing, telomere length measurement, and RNA sequencing. The CIMP subgroups did not correlate significantly with variations in epigenetic regulators. However, the CIMP+ subgroup, associated with better prognosis, showed indicators of longer replicative history, including shorter telomere length (P = 0.015) and older epigenetic (P < 0.001) and mitotic age (P < 0.001). Moreover, the CIMP+ subgroup had significantly higher expression of ANTP homeobox oncogenes, namely TLX3, HOXA9, HOXA10, and NKX2-1, and novel genes in T-ALL biology including PLCB4, PLXND1, and MYO18B. The CIMP- subgroup, with worse prognosis, was associated with higher expression of TAL1 along with frequent STIL-TAL1 fusions (2/40 in CIMP+ vs 11/24 in CIMP-), as well as stronger expression of BEX1. Altogether, our findings suggest different routes for leukemogenic transformation in the T-ALL CIMP subgroups, indicated by different replicative histories and distinct methylomic and transcriptomic profiles. These novel findings can lead to new therapeutic strategies.
儿科 T 细胞急性淋巴细胞白血病(T-ALL)患者的 CIMP(CpG 岛甲基化表型)亚组分类有可能改善当前的风险分层。为了研究这些 CIMP 亚组背后的生物学机制,对北欧儿科 T-ALL 患者的诊断样本进行了全基因组甲基化阵列分析,随后进行了靶向外显子测序、端粒长度测量和 RNA 测序。CIMP 亚组与表观遗传调节剂的变化没有显著相关性。然而,与预后较好相关的 CIMP+亚组表现出更长复制史的迹象,包括较短的端粒长度(P=0.015)和更老的表观遗传(P<0.001)和有丝分裂年龄(P<0.001)。此外,CIMP+亚组中 ANTP 同源盒癌基因,即 TLX3、HOXA9、HOXA10 和 NKX2-1,以及 T-ALL 生物学中的新基因,如 PLCB4、PLXND1 和 MYO18B 的表达水平显著更高。预后较差的 CIMP-亚组与 TAL1 表达水平升高有关,同时频繁出现 STIL-TAL1 融合(CIMP+中为 2/40,CIMP-中为 11/24),以及 BEX1 的表达增强。总之,我们的研究结果表明,T-ALL CIMP 亚组中存在不同的白血病转化途径,这表明存在不同的复制史和不同的甲基组学和转录组学特征。这些新发现可以为新的治疗策略提供依据。